Viscoelastic Emulsion Improved the Bioaccessibility and Oral Bioavailability of Crystalline Compound: A Mechanistic Study Using in Vitro and in Vivo Models.

The oral bioavailability of hydrophobic compound is usually limited by the poor aqueous solubility in the gastrointestinal (GI) tract. Various oral formulations were developed to enhance the systemic concentration of such molecules. Moreover, compounds with high melting temperature that appear as insoluble crystals imposed a great challenge to the development of oral vehicle. Polymethoxyflavone, an emerging category of bioactive compounds with potent therapeutic efficacies, were characterized as having a hydrophobic and highly crystalline chemical structure. To enhance the oral dosing efficiency of polymethoxyflavone, a viscoelastic emulsion system with a high static viscosity was developed and optimized using tangeretin, one of the most abundant polymethoxyflavones found in natural sources, as a modeling compound. In the present study, different in vitro and in vivo models were used to mechanistically evaluate the effect of emulsification on oral bioavailability of tangeretin. In vitro lipolysis revealed that emulsified tangeretin was digested and became bioaccessible much faster than unprocessed tangeretin oil suspension. By simulating the entire human GI tract, TNO's gastrointestinal model (TIM-1) is a valuable tool to mechanistically study the effect of emulsification on the digestion events that lead to a better oral bioavailability of tangeretin. TIM-1 result indicated that tangeretin was absorbed in the upper GI tract. Thus, a higher oral bioavailability can be expected if the compound becomes bioaccessible in the intestinal lumen soon after dosing. In vivo pharmacokinetics analysis on mice again confirmed that the oral bioavailability of tangeretin increased 2.3 fold when incorporated in the viscoelastic emulsion than unformulated oil suspension. By using the combination of in vitro and in vivo models introduced in this work, the mechanism that underlie the effect of viscoelastic emulsion on the oral bioavailability of tangeretin was well-elucidated.

[1]  P. Lam,et al.  Oral delivery of highly lipophilic poorly water-soluble drugs: spray-dried dispersions to improve oral absorption and enable high-dose toxicology studies of a P2Y1 antagonist. , 2014, Journal of pharmaceutical sciences.

[2]  P. Shanthi,et al.  Effect of tangeretin, a polymethoxylated flavone on glucose metabolism in streptozotocin-induced diabetic rats. , 2014, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[3]  Chi-Tang Ho,et al.  Common delivery systems for enhancing in vivo bioavailability and biological efficacy of nutraceuticals , 2014 .

[4]  Chi-Tang Ho,et al.  Design of high-loading and high-stability viscoelastic emulsions for polymethoxyflavones , 2013 .

[5]  Chi-Tang Ho,et al.  Effect of a labile methyl donor on the transformation of 5-demethyltangeretin and the related implication on bioactivity. , 2013, Journal of agricultural and food chemistry.

[6]  D. Mcclements,et al.  Nanoemulsion-based delivery systems for poorly water-soluble bioactive compounds: Influence of formulation parameters on Polymethoxyflavone crystallization. , 2012, Food hydrocolloids.

[7]  Hailong Yu,et al.  Improving the oral bioavailability of curcumin using novel organogel-based nanoemulsions. , 2012, Journal of agricultural and food chemistry.

[8]  Hailong Yu,et al.  Development of a food-grade organogel with high bioaccessibility and loading of curcuminoids , 2012 .

[9]  B. Min,et al.  Tangeretin, a citrus flavonoid, inhibits PGDF-BB-induced proliferation and migration of aortic smooth muscle cells by blocking AKT activation. , 2011, European journal of pharmacology.

[10]  S. Mertens-Talcott,et al.  Pharmacokinetic study of nobiletin and tangeretin in rat serum by high-performance liquid chromatography-electrospray ionization-mass spectrometry. , 2011, Journal of agricultural and food chemistry.

[11]  M. Golding,et al.  The influence of emulsion structure and stability on lipid digestion , 2010 .

[12]  G. Wani,et al.  Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. , 2009, Cancer research.

[13]  Brahmeshwar Mishra,et al.  Lipid--an emerging platform for oral delivery of drugs with poor bioavailability. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  J. Koropatnick,et al.  Tangeretin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells. , 2007, Cancer letters.

[15]  C. Porter,et al.  Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs , 2007, Nature Reviews Drug Discovery.

[16]  Jen-kun Lin,et al.  Tangeretin suppresses IL-1beta-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in human lung carcinoma cells. , 2007, Biochemical pharmacology.

[17]  A. Hoffman,et al.  Use of a Dynamic in Vitro Lipolysis Model to Rationalize Oral Formulation Development for Poor Water Soluble Drugs: Correlation with in Vivo Data and the Relationship to Intra-Enterocyte Processes in Rats , 2006, Pharmaceutical Research.

[18]  Chi-Tang Ho,et al.  Hydroxylated polymethoxyflavones and methylated flavonoids in sweet orange (Citrus sinensis) peel. , 2006, Journal of agricultural and food chemistry.

[19]  A. Theriault,et al.  Modulation of hepG2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone, tangeretin , 2004, Lipids.

[20]  Jen-kun Lin,et al.  Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells. , 2002, Carcinogenesis.

[21]  D. Dexter,et al.  Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease , 2001, Neuroreport.

[22]  S. Gupta,et al.  Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. , 2001, Biochemical and biophysical research communications.

[23]  K. Grohmann,et al.  Phenols in citrus peel byproducts. Concentrations of hydroxycinnamates and polymethoxylated flavones in citrus peel molasses. , 2001, Journal of agricultural and food chemistry.

[24]  D. Dexter,et al.  Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cells in vitro , 2001, Neuropathology and applied neurobiology.

[25]  W. Charman,et al.  Lipid-based vehicles for the oral delivery of poorly water soluble drugs , 1997 .

[26]  M. Miller,et al.  Differential effects of nonhydroxylated flavonoids as inducers of cytochrome P450 1A and 2B isozymes in rat liver. , 1996, Toxicology and applied pharmacology.

[27]  T. Hirano,et al.  Citrus flavone tangeretin inhibits leukaemic HL-60 cell growth partially through induction of apoptosis with less cytotoxicity on normal lymphocytes. , 1995, British Journal of Cancer.

[28]  L. Brissette,et al.  An in vitro model to study lipolysis of rat hepatic very low density lipoprotein using cardiac lipoprotein lipase. , 1984, Canadian journal of biochemistry and cell biology = Revue canadienne de biochimie et biologie cellulaire.

[29]  A. Bast,et al.  Bioprocessing of wheat bran improves in vitro bioaccessibility and colonic metabolism of phenolic compounds. , 2009, Journal of agricultural and food chemistry.

[30]  Chi-Tang Ho,et al.  Validated reversed phase LC method for quantitative analysis of polymethoxyflavones in citrus peel extracts. , 2008, Journal of separation science.

[31]  C. Rhodes,et al.  Controlled-Release Drug Delivery Systems for Prolonged Gastric Residence: An Overview , 1996 .

[32]  C. S. Yang,et al.  Effects of bioflavonoids on hepatic P450 activities. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.